Beijing Beilu Pharmaceutical (300016) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.66 Million ≈ $10.93 Million USD) by net assets (CN¥2.37 Billion ≈ $346.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300016 equity to assets ratio to measure how much of total assets are equity-financed.
Beijing Beilu Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Beijing Beilu Pharmaceutical earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Beijing Beilu Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lander Sports Development Co Ltd
SHE:000558
|
-0.135x |
|
Harum Energy Tbk PT
JK:HRUM
|
0.217x |
|
Shenzhen Textile Holdings Co Ltd
SHE:000045
|
-0.037x |
|
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMII
|
0.000x |
|
Tiptree Inc
NASDAQ:TIPT
|
-0.024x |
|
Gladstone Investment Corporation
NASDAQ:GAIN
|
-0.228x |
|
Hypoport SE
XETRA:HYQ
|
0.012x |
|
Zhejiang He Chuan Technology Corp. Ltd. A
SHG:688320
|
N/A |
Annual Cash Flow Conversion Efficiency for Beijing Beilu Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Beilu Pharmaceutical from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing Beilu Pharmaceutical market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.83 Billion ≈ $267.71 Million |
CN¥163.02 Million ≈ $23.86 Million |
0.089x | +172.27% |
| 2023-12-31 | CN¥1.79 Billion ≈ $261.39 Million |
CN¥58.46 Million ≈ $8.55 Million |
0.033x | -50.75% |
| 2022-12-31 | CN¥1.92 Billion ≈ $281.43 Million |
CN¥127.81 Million ≈ $18.70 Million |
0.066x | +27.42% |
| 2021-12-31 | CN¥2.08 Billion ≈ $305.05 Million |
CN¥108.73 Million ≈ $15.91 Million |
0.052x | -43.93% |
| 2020-12-31 | CN¥1.89 Billion ≈ $276.87 Million |
CN¥176.00 Million ≈ $25.75 Million |
0.093x | -13.95% |
| 2019-12-31 | CN¥1.45 Billion ≈ $212.25 Million |
CN¥156.81 Million ≈ $22.95 Million |
0.108x | -25.83% |
| 2018-12-31 | CN¥1.21 Billion ≈ $176.45 Million |
CN¥175.75 Million ≈ $25.72 Million |
0.146x | +7.54% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.46 Million |
CN¥144.92 Million ≈ $21.21 Million |
0.136x | +60.46% |
| 2016-12-31 | CN¥901.69 Million ≈ $131.95 Million |
CN¥76.17 Million ≈ $11.15 Million |
0.084x | -2.56% |
| 2015-12-31 | CN¥932.63 Million ≈ $136.47 Million |
CN¥80.85 Million ≈ $11.83 Million |
0.087x | +37.19% |
| 2014-12-31 | CN¥666.33 Million ≈ $97.51 Million |
CN¥42.11 Million ≈ $6.16 Million |
0.063x | -14.55% |
| 2013-12-31 | CN¥559.38 Million ≈ $81.86 Million |
CN¥41.37 Million ≈ $6.05 Million |
0.074x | +69.54% |
| 2012-12-31 | CN¥523.96 Million ≈ $76.67 Million |
CN¥22.86 Million ≈ $3.34 Million |
0.044x | -53.12% |
| 2011-12-31 | CN¥491.47 Million ≈ $71.92 Million |
CN¥45.73 Million ≈ $6.69 Million |
0.093x | +15.98% |
| 2010-12-31 | CN¥467.62 Million ≈ $68.43 Million |
CN¥37.51 Million ≈ $5.49 Million |
0.080x | -39.92% |
| 2009-12-31 | CN¥433.71 Million ≈ $63.46 Million |
CN¥57.91 Million ≈ $8.47 Million |
0.134x | +473.67% |
| 2008-12-31 | CN¥133.23 Million ≈ $19.50 Million |
CN¥-4.76 Million ≈ $-696.67K |
-0.036x | -126.30% |
| 2007-12-31 | CN¥90.33 Million ≈ $13.22 Million |
CN¥12.28 Million ≈ $1.80 Million |
0.136x | -50.49% |
| 2006-12-31 | CN¥71.59 Million ≈ $10.48 Million |
CN¥19.65 Million ≈ $2.88 Million |
0.274x | -- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more